Literature DB >> 19604233

Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.

Alberto Alvarez-Larrán1, Beatriz Bellosillo, Luz Martínez-Avilés, Silvia Saumell, Antonio Salar, Eugenia Abella, Eva Gimeno, Sergi Serrano, Lourdes Florensa, Blanca Sánchez, Carmen Pedro, Carles Besses.   

Abstract

Postpolycythaemic myelofibrosis (PPMF) is a known complication of polycythaemia vera (PV) but information regarding its incidence and predisposing factors is not well defined. In 116 subjects consecutively diagnosed with PV in a single institution (median age 62 years, range: 20-88), the probability of PPMF was analysed by the Kaplan-Meier method, followed by the log-rank test. With a mean follow-up of 8 years (95% confidence interval: 6.6-9), 17 patients had evolved into PPMF (15%). The probability of evolution to PPMF was 16% at 10 years and 34% at 15 years. Age, gender, spleen size, leucocytosis, thrombocytosis or cytoreductive treatment were not associated with an increased risk of PPMF. The actuarial probability of PPMF at 15 years was higher in those patients presenting at diagnosis with endogenous megakaryocytic colony formation (59% when present versus 10% when absent, P = 0.03), an elevated serum lactate dehydrogenase (LDH) level (69% vs. 23% in patients with normal LDH, P = 0.04), and in those who were heterozygous for the JAK2 V617F mutation (55% vs. 17% in heterozygotes, P = 0.04). In conclusion, PPMF is a frequent complication in PV patients at 15 years with the risk being higher in patients with increased LDH, endogenous megakaryocytic colony formation or a high JAK2 V617F allele burden.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604233     DOI: 10.1111/j.1365-2141.2009.07804.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Carme Pedro; Francesc García-Pallarols; Luz Martínez-Avilés; Beatriz Bellosillo; Carlos Besses
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

2.  Optimized and Personalized Phlebotomy Schedules for Patients Suffering From Polycythemia Vera.

Authors:  Patrick Lilienthal; Manuel Tetschke; Enrico Schalk; Thomas Fischer; Sebastian Sager
Journal:  Front Physiol       Date:  2020-04-17       Impact factor: 4.566

3.  The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Montse Gómez; Concepción Boqué; Francisca Ferrer-Marín; José-María Raya; Valentín García-Gutiérrez; Ana Kerguelen; Blanca Xicoy; Pere Barba; Jesús Martínez; Elisa Luño; Alberto Alvarez-Larrán; Joaquín Martínez-López; Elisa Arbelo; Carles Besses
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

4.  Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.

Authors:  Lukas Ronner; Nikolai Podoltsev; Jason Gotlib; Mark L Heaney; Andrew T Kuykendall; Casey O'Connell; Jamile Shammo; Angela G Fleischman; Robyn M Scherber; Ruben Mesa; Abdulraheem Yacoub; Cecelia Perkins; Shelby Meckstroth; Lindsey Behlman; Matthew Chiaramonte; Mahta Salehi; Kimia Ziadkhanpour; Hellen Nguyen; Olivia Siwoski; Annie Kwok Hung; Michelle Janania Martinez; Jenny Nguyen; Sagar Patel; Revathi Kollipara; Ami Dave; Megan Randall; Michael Grant; Mitchell Harrison; Paola Fernandez Soto; Douglas Tremblay; Ronald Hoffman; Erin Moshier; John Mascarenhas
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

Review 5.  Polycythemia vera.

Authors:  Raffaele Landolfi; Maria Anna Nicolazzi; Angelo Porfidia; Leonardo Di Gennaro
Journal:  Intern Emerg Med       Date:  2010-03-16       Impact factor: 3.397

6.  Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Yoshitaka Sunami; Yumi Hironaka; Masaaki Noguchi; Michiaki Koike; Eriko Sato; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-12-19       Impact factor: 2.490

Review 7.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

8.  Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Authors:  Lucia Masarova; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Kate J Newberry; Taghi Manshouri; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-02       Impact factor: 3.156

Review 9.  Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Authors:  Aziz Nazha; Aaron T Gerds
Journal:  Oncologist       Date:  2016-03-14

Review 10.  Jak-2 positive myeloproliferative neoplasms.

Authors:  Pablo J Muxí; Ana Carolina Oliver
Journal:  Curr Treat Options Oncol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.